Life sciences, clinical and bioanalytical contract solutions provider SGS has obtained preliminary data from a controlled human infection trial with FluGen Inc.’s investigational M2SR vaccine from a study carried out at the company’s human challenge facility within its clinical pharmacology unit in Antwerp, Belgium. The trial was designed to assess the protective efficacy of the vaccine against infection and illness with the SGS H3N2 A/Belgium challenge agent which was launched in 2017 following a full GMP-compliant manufacturing process. The recent study aimed to assess whether the vaccine could induce broadly protective immune responses and protect against the substantially mismatched SGS challenge strain.
In the trial, healthy adults were randomised to receive either placebo or a single intranasal dose of M2SR vaccine. After completing the vaccination stage of the study, 99 subjects were challenged with A/Belgium and then assessed for markers regarding safety, viral shedding (vAUC) and relevant clinical signs and symptoms. Subjects are being followed out to four months from challenge to ensure a full and uneventful recovery. Currently, all subjects have competed the isolation element with the study’s completion scheduled for Q2 2019.
Topline results showed vaccine efficacy against the substantially drifted challenge virus, despite a mismatch greater than that seen between the marketed, injectable seasonal vaccine and the predominant influenza A virus strains in 2014-15.
“Our goal in manufacturing a novel, non-hemagglutinating, influenza A H3N2 strain to use as a challenge agent was to improve current disease modelling and help research efforts to combat the very real threat that is posed by the influenza virus to global populations,” commented Adrian Wildfire, Scientific Director at SGS. “It is heartening to see that, following a record year for hospitalisations and infant deaths from H3N2 in 2017-2018, findings are very positive for FluGen’s M2SR and they confirm the strong results seen in previous Phase 1 immunogenicity and preclinical challenge studies. Also, this study serves to reaffirm the antigenic relevance of the A/Belgium challenge agent and validates our controlled human infection model in assisting in the selection and development of next-generation vaccines.”
For further information about SGS visit www.sgs.com
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- Chemspace and LabNetwork collaborate to extend access to chemical databases
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- EVENT REVIEW: Busy sessions at BIO-Europe Spring!
- COMPANY UPDATE: Metrion Biosciences and the potential for ion channel drug discovery